ストックスクリーナーアプリを入手
16.85
2.18%
0.36
前日終値:
$16.49
開ける：
$16.39
24時間の取引高:
103.30K
Relative Volume:
0.45
時価総額：
$307.49M
収益：
$116.88M
当期純損益:
$-25.09M
株価収益率:
-120.36
EPS:
-0.14
ネットキャッシュフロー:
$-20.74M
1週間 パフォーマンス:
+3.63%
1か月 パフォーマンス:
-19.88%
6か月 パフォーマンス:
+11.29%
1年 パフォーマンス:
+51.80%
1日の値動き範囲:
$16.11
$17.10
1週間の範囲:
$15.81
$17.66
52週間の値動き範囲:
$7.4843
$29.82
Rigel Pharmaceuticals Stock (RIGL) Company Profile
名前
Rigel Pharmaceuticals
セクター
電話
650-624-1100
住所
611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO, CA
RIGL を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RIGL
Rigel Pharmaceuticals
|
16.85 | 307.49M | 116.88M | -25.09M | -20.74M | -0.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Rigel Pharmaceuticals Stock (RIGL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-04-03 | 再開されました | Piper Sandler | Neutral |
| 2022-06-09 | ダウングレード | Citigroup | Buy → Neutral |
| 2022-06-08 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2022-06-08 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2022-03-23 | 開始されました | B. Riley Securities | Neutral |
| 2020-11-09 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2019-11-15 | 再開されました | Cantor Fitzgerald | Overweight |
| 2019-09-26 | 再開されました | JP Morgan | Overweight |
| 2019-03-01 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2018-08-27 | 開始されました | Citigroup | Buy |
| 2018-05-02 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2017-12-21 | 再開されました | Piper Jaffray | Overweight |
| 2017-12-15 | 開始されました | Cantor Fitzgerald | Overweight |
| 2017-11-06 | 再開されました | H.C. Wainwright | Buy |
| 2017-03-09 | 繰り返されました | H.C. Wainwright | Buy |
| 2016-08-31 | 繰り返されました | H.C. Wainwright | Buy |
| 2016-08-30 | 繰り返されました | Piper Jaffray | Overweight |
| 2016-07-13 | 開始されました | H.C. Wainwright | Buy |
| 2016-06-13 | 開始されました | Piper Jaffray | Overweight |
| 2016-04-22 | アップグレード | JP Morgan | Neutral → Overweight |
| 2013-04-08 | 繰り返されました | Stifel | Buy |
| 2012-11-29 | 開始されました | UBS | Neutral |
| 2012-11-06 | 繰り返されました | Oppenheimer | Outperform |
| 2012-03-26 | 開始されました | Canaccord Genuity | Hold |
| 2010-12-10 | ダウングレード | MP Advisors | Outperform → Market Perform |
すべてを表示
Rigel Pharmaceuticals (RIGL) 最新ニュース
Rigel (RIGL) Upgraded to Buy: What Does It Mean for the Stock? - Nasdaq
Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - MarketScreener
Stocks That Fell to 3-Year Lows in the Week of Sept. 13 - GuruFocus
Where are the Opportunities in (RIGL) - news.stocktradersdaily.com
Rigel Pharmaceuticals: 3-Drug Company Reaches Profitability (RIGL) - Seeking Alpha
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - PR Newswire
High Growth Tech Stocks in the US for April 2025 - simplywall.st
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Not Doing Enough For Some Investors As Its Shares Slump 26% - simplywall.st
Rigel settles patent litigation regarding its immune thrombocytopenia treatment - MSN
Rigel settles patent litigation over TAVALISSE treatment By Investing.com - Investing.com South Africa
Rigel Pharma stock rises on patent settlement (RIGL:NASDAQ) - Seeking Alpha
Rigel, Hetero Settle Patent Suit Over Platelet-Booster Tavalisse - Bloomberg Law News
Rigel climbs on blood disorder drug patent settlement - TradingView
Rigel settles patent litigation regarding its immune thrombocytopenia treatment (RIGL:NASDAQ) - Seeking Alpha
Rigel Pharma Settles Tavalisse Patent Litigation With Annora Pharma - Nasdaq
Rigel Pharmaceuticals Settles Patent Litigation Over Tavalisse - MarketScreener
Rigel Pharmaceuticals resolves patent litigation related to Tavalisse - TipRanks
Rigel Announces Settlement Agreement Resolving TAVALISSE® (Fostamatinib Disodium Hexahydrate) Patent Litigation - Marketscreener.com
Rigel settles patent litigation over TAVALISSE treatment - Investing.com
Rigel Announces Settlement Agreement Resolving TAVALISSE® (fostamatinib disodium hexahydrate) Patent Litigation - PR Newswire
Rigel Wins Patent Battle: TAVALISSE Exclusivity Protected Until 2032 in Major Settlement - Stock Titan
(RIGL) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Bristol-Myers Squibb expands immuno-oncology pipeline with Flexus Biosciences, Rigel Pharmaceuticals deals - FirstWord Pharma
Rigel Pharmaceuticals appoints Mark W. Frohlich to board of directors - MSN
Statutory Profit Doesn't Reflect How Good Rigel Pharmaceuticals' (NASDAQ:RIGL) Earnings Are - Yahoo Finance
(RIGL) Investment Analysis and Advice - news.stocktradersdaily.com
Rigel Pharmaceuticals’ SWOT analysis: pipeline potential drives stock outlook - Investing.com India
Rigel Pharmaceuticals’ SWOT analysis: pipeline potential drives stock outlook By Investing.com - Investing.com South Africa
Rigel Looks Interesting, But Let's Wait For A Lower Price (NASDAQ:RIGL) - Seeking Alpha
Rigel Pharmaceuticals appoints new board member By Investing.com - Investing.com Australia
Rigel Pharmaceuticals adds oncology expert to board By Investing.com - Investing.com Australia
SEC Form 4 filed by Director Frohlich Mark W - Quantisnow
Rigel Pharmaceuticals appoints new board member - Investing.com
Rigel Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update - Quantisnow
Rigel Pharmaceuticals Appoints Dr. Frohlich to Board - TipRanks
Rigel appoints Mark W. Frohlich to its board -March 10, 2025 at 12:01 pm EDT - Marketscreener.com
Rigel Pharmaceuticals adds oncology expert to board - Investing.com India
Rigel Appoints Mark W. Frohlich, M.D. to Board of Directors - StockTitan
Rhumbline Advisers Has $423,000 Stock Position in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - Defense World
FY2025 EPS Estimates for RIGL Increased by Cantor Fitzgerald - Defense World
Citigroup Forecasts Strong Price Appreciation for Rigel Pharmaceuticals (NASDAQ:RIGL) Stock - Defense World
Rigel Pharmaceuticals Implements 1-for-10 Reverse Stock Split: Balancing Nasdaq Compliance and Investor Appeal - MSN
Rigel Pharmaceuticals (NASDAQ:RIGL) Downgraded by StockNews.com to “Buy” - Defense World
What is B. Riley’s Forecast for RIGL Q1 Earnings? - Defense World
What is HC Wainwright’s Estimate for RIGL Q1 Earnings? - Defense World
Earnings call transcript: Rigel Pharmaceuticals Q4 2024 sees strong growth By Investing.com - Investing.com Australia
Rigel Pharmaceuticals, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next - Yahoo Finance
Rigel Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
B. Riley Forecasts Strong Price Appreciation for Rigel Pharmaceuticals (NASDAQ:RIGL) Stock - Defense World
HC Wainwright Reiterates Buy Rating for Rigel Pharmaceuticals (NASDAQ:RIGL) - Defense World
What is B. Riley’s Estimate for RIGL FY2026 Earnings? - Defense World
Rigel Pharmaceuticals (RIGL) 財務データ
収益
当期純利益
現金流量
EPS
2.51%
大文字化:
|
ボリューム (24 時間):